Challenges in Performing Real-World Evidence Studies in Low-Middle Income Countries: the EdoBRA Study.
作者信息
Massaro Ayrton Roberto
机构信息
Hospital Sírio-libanês - Neurologia, São Paulo, SP - Brasil.
出版信息
Arq Bras Cardiol. 2025 Jul 28;122(4):e20250353. doi: 10.36660/abc.20250353. eCollection 2025.
Abstract
摘要
相似文献
1
Challenges in Performing Real-World Evidence Studies in Low-Middle Income Countries: the EdoBRA Study.在低收入和中等收入国家开展真实世界证据研究的挑战：埃多布拉研究
Arq Bras Cardiol. 2025 Jul 28;122(4):e20250353. doi: 10.36660/abc.20250353. eCollection 2025.
2
Interventions for improving coverage of childhood immunisation in low- and middle-income countries.改善中低收入国家儿童免疫接种覆盖率的干预措施。
Cochrane Database Syst Rev. 2023 Dec 6;12(12):CD008145. doi: 10.1002/14651858.CD008145.pub4.
3
Measurement of social capital in relation to health in low and middle income countries (LMIC): a systematic review.测量中低收入国家（LMIC）社会资本与健康的关系：系统评价。
Soc Sci Med. 2015 Mar;128:95-104. doi: 10.1016/j.socscimed.2015.01.005. Epub 2015 Jan 8.
4
Post-Asphyxial Aftercare and Management of Neonates in Low- and Middle-Income Countries: A Systematic Evidence Synthesis.低收入和中等收入国家新生儿窒息后护理与管理：系统证据综合分析
Neonatology. 2025;122(Suppl 1):84-105. doi: 10.1159/000541862. Epub 2024 Nov 13.
5
The effect of pharmacist-provided non-dispensing services on patient outcomes, health service utilisation and costs in low- and middle-income countries.药剂师提供的非配药服务对低收入和中等收入国家患者结局、卫生服务利用及成本的影响。
Cochrane Database Syst Rev. 2013 Feb 28;2013(2):CD010398. doi: 10.1002/14651858.CD010398.
6
Cervical cancer trends, HPV vaccine utilization, and screening in low- and lower-middle-income countries: an updated review.低收入和中低收入国家的宫颈癌趋势、人乳头瘤病毒疫苗接种情况及筛查：最新综述
Ther Adv Vaccines Immunother. 2025 Jul 24;13:25151355251356646. doi: 10.1177/25151355251356646. eCollection 2025.
7
Digital interventions for common mental health problems among older adults in low- and middle-income countries: a scoping review.低收入和中等收入国家老年人常见心理健康问题的数字干预措施：一项范围综述
BMJ Glob Health. 2025 Jun 24;10(6):e017836. doi: 10.1136/bmjgh-2024-017836.
8
End-stage paediatric heart failure in low- and middle-income countries: challenges in surgical management.低收入和中等收入国家的终末期小儿心力衰竭：外科治疗面临的挑战
Indian J Thorac Cardiovasc Surg. 2025 Jun;41(6):768-783. doi: 10.1007/s12055-024-01853-z. Epub 2024 Nov 25.
9
Centre-based day care for children younger than five years of age in low- and middle-income countries.低收入和中等收入国家针对五岁以下儿童的日间中心照料服务。
Cochrane Database Syst Rev. 2014 Sep 25;2014(9):CD010543. doi: 10.1002/14651858.CD010543.pub2.
10
A systematic review of public health interventions to address breast cancer inequalities in low- and middle-income countries.系统评价公共卫生干预措施在解决中低收入国家乳腺癌不平等问题中的作用。
Syst Rev. 2024 Jul 25;13(1):195. doi: 10.1186/s13643-024-02620-2.
本文引用的文献
1
Effectiveness and Safety of Edoxaban in the Routine Clinical Care of Atrial Fibrillation Patients in Brazil: Prospective 1-Year Follow-Up Study - EdoBRA.依度沙班在巴西心房颤动患者常规临床护理中的有效性和安全性：前瞻性1年随访研究 - EdoBRA
Arq Bras Cardiol. 2025 Apr 14;122(4):e20240589. doi: 10.36660/abc.20240589. eCollection 2025.
2
Atrial fibrillation burden in clinical practice, research, and technology development: a clinical consensus statement of the European Society of Cardiology Council on Stroke and the European Heart Rhythm Association.临床实践、研究及技术开发中的房颤负荷：欧洲心脏病学会卒中委员会与欧洲心律协会的临床共识声明
Europace. 2025 Mar 5;27(3). doi: 10.1093/europace/euaf019.
3
Two-Year Follow-Up of Patients With Atrial Fibrillation Receiving Edoxaban in Routine Clinical Practice: Results From the Global ETNA-AF Program.接受依度沙班治疗的房颤患者在常规临床实践中的两年随访：全球ETNA-AF项目的结果
Clin Cardiol. 2025 Feb;48(3):e70091. doi: 10.1002/clc.70091.
4
Risk of Recurrent Stroke, Mortality, and Intracerebral Hemorrhage in Patients With Atrial Fibrillation Detected Before or After a Stroke.中风之前或之后检测出心房颤动的患者复发性中风、死亡率和脑出血的风险
Neurology. 2025 Mar 25;104(6):e213426. doi: 10.1212/WNL.0000000000213426. Epub 2025 Feb 25.
5
Characteristics Associated with Prevalent Atrial Fibrillation and Risk Profile for Incident Atrial Fibrillation an Elderly Population from ELSA-Brasil.与巴西老年人队列中房颤患病率及新发房颤风险特征相关的因素
Arq Bras Cardiol. 2025 Jan;122(1):e20240487. doi: 10.36660/abc.20240487.
6
The impact of competing stroke etiologies in patients with atrial fibrillation.房颤患者中竞争的卒中病因的影响。
Eur Stroke J. 2023 Sep;8(3):703-711. doi: 10.1177/23969873231185220. Epub 2023 Jul 4.
7
Edoxaban Versus Warfarin in Latin American Patients With Atrial Fibrillation: The ENGAGE AF-TIMI 48 Trial.依度沙班与华法林用于拉丁美洲房颤患者的比较：ENGAGE AF-TIMI 48 试验
J Am Coll Cardiol. 2018 Sep 25;72(13):1466-1475. doi: 10.1016/j.jacc.2018.07.037.
8
Edoxaban versus warfarin in patients with atrial fibrillation.依度沙班与华法林用于房颤患者。
N Engl J Med. 2013 Nov 28;369(22):2093-104. doi: 10.1056/NEJMoa1310907. Epub 2013 Nov 19.
9
Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.荟萃分析：抗栓治疗预防非瓣膜性心房颤动患者的卒中
Ann Intern Med. 2007 Jun 19;146(12):857-67. doi: 10.7326/0003-4819-146-12-200706190-00007.
10
Misuse of antithrombotic therapy in atrial fibrillation patients: frequent, pervasive and persistent.
J Thromb Thrombolysis. 2007 Feb;23(1):65-71. doi: 10.1007/s11239-006-9012-9.
Zotero 插件